Japan, AstraZeneca agree on 120 million doses of coronavirus vaccine

/ 11:13 AM August 09, 2020

TOKYO — The government has reached a supply deal with British drugmaker giant AstraZeneca PLC for 120 million doses of a coronavirus vaccine.

Health, Labor and Welfare Minister Katsunobu Kato said at a press conference Friday that Japan is to receive the vaccine from early next year, with 30 million doses to be supplied by March, should AstraZeneca succeed in developing the drug.


AstraZeneca, which is developing the vaccine in collaboration with the University of Oxford, is in the final stages of clinical trials and is aiming to commercialize the vaccine in September.

The company will begin clinical trials in Japan this month to confirm the safety and effectiveness of the vaccine when it is administered to Japanese, he said.


The firm has yet to decide whether the vaccine will be administered once or twice per person. The vaccine supply is equivalent to at least 60 million people.

“We will continue to discuss with other vaccine manufacturers as well,” Kato said at the press conference.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.
View comments

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: AstraZeneca, Coronavirus, coronavirus outbreak, coronavirus pandemic, COVID-19, COVID-19 Vaccine, Japan
For feedback, complaints, or inquiries, contact us.

© Copyright 1997-2020 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.